| Collin Trevor Durham, MD | |
|
1201 Pleasant Valley Rd, Owensboro, KY 42303-9811 | |
| (270) 417-2000 | |
| Not Available |
| Full Name | Collin Trevor Durham |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 1201 Pleasant Valley Rd, Owensboro, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194288597 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | R77320 (Arizona) | Secondary |
| 207R00000X | Internal Medicine | 56335 (Kentucky) | Primary |
| Entity Name | Owensboro Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235518242 PECOS PAC ID: 0648255034 Enrollment ID: O20040621000818 |
News Archive
If you have an overactive bladder or incontinence, help could be on the way. A new research report published online in the FASEB Journal, shows that the epithelium, a thin layer of cells which line the surface of the bladder, is able to sense how full the bladder is through the action of a family of proteins called integrins.
The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).
Pfizer Inc. announced today that the European Commission has granted conditional marketing authorization for BOSULIF (bosutinib) in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Collin Trevor Durham, MD Po Box 23229, Owensboro, KY 42304-3229 Ph: () - | Collin Trevor Durham, MD 1201 Pleasant Valley Rd, Owensboro, KY 42303-9811 Ph: (270) 417-2000 |
News Archive
If you have an overactive bladder or incontinence, help could be on the way. A new research report published online in the FASEB Journal, shows that the epithelium, a thin layer of cells which line the surface of the bladder, is able to sense how full the bladder is through the action of a family of proteins called integrins.
The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company's efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).
Pfizer Inc. announced today that the European Commission has granted conditional marketing authorization for BOSULIF (bosutinib) in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.
› Verified 6 days ago
David B. Olalekan, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 Pleasant Valley Rd, Owensboro, KY 42303 Phone: 270-417-4700 Fax: 270-417-4709 | |
Dr. Jacob S. Hodskins, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Breckenridge St, Suite 400, Owensboro, KY 42303 Phone: 270-688-3445 Fax: 270-688-3344 | |
Dr. Adrian James Yeiser, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 811 E Parrish Ave, Owensboro, KY 42303 Phone: 270-688-3371 Fax: 270-688-3370 | |
Dr. Roshan K. Mathew, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3110 Fairview Dr, Owensboro, KY 42303 Phone: 270-240-2129 | |
Madison P Hardesty, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1201 Pleasant Valley Rd, Owensboro, KY 42303 Phone: 270-417-4700 Fax: 270-417-4709 | |
Dr. David M Brey, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Breckenridge St Ste 303, Owensboro, KY 42303 Phone: 270-688-5100 Fax: 270-688-5109 | |
Mahesh K. Moolani, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1200 Breckenridge St, Owensboro, KY 42303 Phone: 270-685-8224 Fax: 270-685-8228 |